<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C29C7BF4-3F59-4AD7-BD57-E1CBF1B38609"><gtr:id>C29C7BF4-3F59-4AD7-BD57-E1CBF1B38609</gtr:id><gtr:name>Biomimox Ltd</gtr:name><gtr:address><gtr:line1>98 Newland</gtr:line1><gtr:city>Witney</gtr:city><gtr:postCode>OX28 3JQ</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C29C7BF4-3F59-4AD7-BD57-E1CBF1B38609" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>C29C7BF4-3F59-4AD7-BD57-E1CBF1B38609</gtr:id><gtr:name>Biomimox Ltd</gtr:name><gtr:address><gtr:line1>98 Newland</gtr:line1><gtr:city>Witney</gtr:city><gtr:postCode>OX28 3JQ</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>7200.0</gtr:offerGrant><gtr:projectCost>12000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E04E9313-1EBB-4852-9DA3-0B29983B675A"><gtr:id>E04E9313-1EBB-4852-9DA3-0B29983B675A</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Sharpe</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700471"><gtr:id>1ECD75D2-8B09-4791-8DC9-D0D6363AD7DD</gtr:id><gtr:title>Proof of Market for Periplasmic Affinity Capture and Novel Aptamer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700471</gtr:grantReference><gtr:abstractText>BioMimOx is developing a novel method of protein engineering that enables highly specific
binding of proteins to targets of interest. The method of protein engineering is termed
Periplasmic Affinity Capture and makes use of bacterial cell?s ability to produce proteins
from laboratory engineered DNA. The resulting binding proteins are termed peptide aptamers
and have a great number of uses within the fields of biotherapeutics (protein therapeutics),
diagnostics and research reagents.
We intend to use these platform technologies to enter the protein purification segment of the
biotherapeutics market in order to improve existing technologies. The biotherapeutics market
is forecast to be worth $168 billion by 2017 and downstream processing such as protein
purification is estimated to make up 80% of production costs.
There are two classes of protein therapeutics; monoclonal antibodies (mAbs) which are the
fastest growing class in the pharmaceutical industry and non-monoclonal antibody proteins
(non-mAbs). Both these classes of protein therapeutics make use of different technologies in
their purification. MAb purification uses a bacterially derived protein known as Protein A,
which are toxic to humans but have a very high affinity to mAbs. This unique coupling can
be used to separate out mAbs from impurities in downstream processing. Currently, Protein
A is allowed for this purpose by the Federal Drug Administration (FDA) in the approval
process but alternatives are being sought. Non-mAbs are purified using technology that has
not changed a great deal over for 30 years. As this is a multistep procedure it suffers from
low yields and is costly. By producing proteins with a high affinity for the therapeutic
protein, we can provide an alternative to Protein A in mAb purification and to introduce a
much needed platform technology to the purification of non-mAbs therefore streamlining the
process, increasing total yields and reducing costs.</gtr:abstractText><gtr:fund><gtr:end>2015-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>7200</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700471</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>